R Scott Turner, PhD, MD

Articles by R Scott Turner, PhD, MD

Patient Selection for Lecanemab to Treat Early Alzheimer Dementia: Details with R Scott Turner, PhD, MD

ByR Scott Turner, PhD, MD,Grace Halsey

January 28th 2025

Dr Turner reviews the profile of the individual who is most likely to benefit from lecanemab therapy.

Lecanemab Monthly IV Maintenance Dosing: Research Highlights with R Scott Turner, PhD, MD

ByR Scott Turner, PhD, MD,Grace Halsey

January 27th 2025

Georgetown University memory disorders expert R Scott Turner, PhD, MD, reviews the science behind approval of lecanemab for monthly maintenance dosing of lecanemab.

Anti-Amyloid Antibodies in Short: R Scott Turner, PhD, MD Explains

ByR Scott Turner, PhD, MD,Grace Halsey

January 24th 2025

The revolutionary medications are the first new treatments for Alzheimer disease to be approved in more than 20 years and the first-ever disease-modifying drugs.

R Scott Turner, PhD, MD

Articles by R Scott Turner, PhD, MD

Patient Selection for Lecanemab to Treat Early Alzheimer Dementia: Details with R Scott Turner, PhD, MD

Lecanemab Monthly IV Maintenance Dosing: Research Highlights with R Scott Turner, PhD, MD

Anti-Amyloid Antibodies in Short: R Scott Turner, PhD, MD Explains

Latest Updated Articles

Trending on Patient Care Online

Plasma Biomarkers Achieve High Accuracy for Confirmatory Aβ Positivity in Eligibility Test for DMT in Alzheimer Disease

Pooled Safety Analysis Supports Elinzanetant for Vasomotor Symptoms Through 52 Weeks

Provider Specialty and Type Drive Divergent Prescribing Patterns for Symptoms of Menopause

Orforglipron Achieves Up to 12% Weight Loss in Obesity Phase 3 Study: Daily Dose

Grail Reports Strong Performance for Galleri Blood Test Ahead of FDA Submission